TipRanks
Go Ultimate55% OFF

Knight Therapeutics (04K) Stock Forecast & Price Target

See the Price Targets and Ratings of:All AnalystsTop AnalystsPremium

04K Analyst Ratings

Strong Buy
3Ratings
3Buy0Hold0Sell
Based on 3 analysts giving stock ratings to Knight Therapeutics in the past 3 months

04K Stock 12 Month Forecast

EUR 7.50▲(3.49% Upside)
Based on 3 Wall Street analysts offering 12 month price targets for Knight Therapeutics in the last 3 months. The average price target is EUR 7.50 with a high forecast of EUR 7.82 and a low forecast of EUR 7.02. The average price target represents a 3.49% change from the last price of EUR 7.25.
Highest Price TargetEUR 7.82Average Price TargetEUR 7.50Lowest Price TargetEUR 7.02

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for DE:04K
Analyst ProfileExpert FirmPrice TargetPositionUpside / DownsideActionDateFollowArticle
Stifel NicolausEUR 7.02→EUR 7.82buy7.89%UpsideReiterated10/16/26
RBC CapitalEUR 6.07→EUR 7.02buy-3.12%DownsideReiterated08/07/26
Bloom BurtonEUR 7.66buy5.69%UpsideReiterated08/07/26
Canaccord GenuityEUR 6.07buy-16.33%DownsideInitiated05/08/26
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AORTArtivion
MDWDMediwound
IMUXImmunic
RZLTRezolute
DFTXDefinium Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Knight Therapeutics

3 Months
Tania Armstrong-Whitworth
Tania Armstrong-WhitworthCanaccord Genuity
Success Rate11/16 ratings generated profit
69%
Average Return
+2.06%

Copying Tania Armstrong-Whitworth's trades and holding each position for 3 Months would result in 68.75% of your transactions generating a profit, with an average return of +2.06% per trade.

1 Year
Douglas Miehm
Douglas MiehmRBC Capital
Success Rate17/27 ratings generated profit
63%
Average Return
+12.11%

Copying Douglas Miehm's trades and holding each position for 1 Year would result in 62.96% of your transactions generating a profit, with an average return of +12.11% per trade.

2 Years
Douglas Miehm
Douglas MiehmRBC Capital
Success Rate18/27 ratings generated profit
67%
Average Return
+28.39%

Copying Douglas Miehm's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +28.39% per trade.

04K Analyst Recommendation Trends

02468Oct 25Nov 25Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26
Monthly rating counts for 04K
RatingMay 26Jun 26Jul 26Aug 26Sep 26
Strong Buy00000
Buy44334
Hold00000
Sell00000
Strong Sell00000
total44334

In the current month, 04K has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 04K average Analyst price target in the past 3 months is 7.50.

04K Financial Forecast

EUR -2EUR -1.25EUR -0.5EUR 0.25EUR 1Q4 2025Q2 2026Q3 2026
HighEUR 0.02
ConsensusEUR 0.01
LowEUR -0.01

04K Earnings Forecast

Next quarter’s earnings estimate for 04K is EUR 0.01 with a range of -EUR 0.01 to EUR 0.02. The previous quarter’s EPS was -EUR 0.02. 04K beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 04K has Performed in-line its overall industry.

EUR 77.6MEUR 81.9MEUR 86.2MEUR 90.5MEUR 94.8MQ4 2025Q2 2026Q3 2026
HighEUR 84.4M
ConsensusEUR 82.5M
LowEUR 80.8M

04K Sales Forecast

Next quarter’s sales forecast for 04K is EUR 82.51M with a range of EUR 80.85M to EUR 84.36M. The previous quarter’s sales results were EUR 92.09M. 04K beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 04K has Performed in-line its overall industry.

04K Stock Forecast FAQ

What is DE:04K’s average 12-month price target, according to analysts?
Based on analyst ratings, Knight Therapeutics’s 12-month average price target is €7.50.
What is DE:04K’s upside potential, based on the analysts’ average price target?
Knight Therapeutics has 3.49% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Knight Therapeutics a Buy, Sell or Hold?
Knight Therapeutics has a consensus rating of Strong Buy, which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
What is Knight Therapeutics’s share price target?
The average share price target for Knight Therapeutics is €7.50. This is based on 3 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €7.82, and the lowest forecast is €7.02. The average share price target represents a 3.49% increase from the current price of €7.25.
What do analysts say about Knight Therapeutics?
Knight Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Street analysts.
How can I buy shares of Knight Therapeutics?
To buy shares of DE:04K, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.